
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is a clinical-stage company specializing in developing treatments for genetically driven neuromuscular diseases using its proprietary FORCE platform. Despite the potential risks associated with its platform and regulatory pathway, Dyne's lead programs have shown promising biomarker and functional improvements, with a potential launch timeline of 1H28 for its lead program, Z-basivarsen. Additionally, Dyne has a diverse pipeline of candidates targeting various indications, with potential market opportunities in FSHD and Pompe disease. Overall, these factors suggest a positive outlook for Dyne Therapeutics with potential for long-term growth and success.
Bears say
Dyne Therapeutics is a clinical-stage neuromuscular disease company with a focused mission. However, the company is currently facing intense competition in the gene therapies and oligonucleotide medicines space, and its pipeline of therapies is still in the early stages of development. There is also a risk of future dilution for investors if the company needs to raise capital to support its research and development efforts. The company's current valuation is supported by the potential of their lead candidate Z-rostudirsen for Duchenne muscular dystrophy, but this success may not be replicated by other pipeline assets.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares